{
    "clinical_study": {
        "@rank": "132637", 
        "arm_group": [
            {
                "arm_group_label": "PolyHeal 2", 
                "arm_group_type": "Experimental", 
                "description": "Negatively charged 5-micron polystyrene microspheres in Water For Injection"
            }, 
            {
                "arm_group_label": "PolyHeal", 
                "arm_group_type": "Active Comparator", 
                "description": "Negatively charged 5-micron polystyrene microspheres suspended in Dulbecco's Modified Eagle's Medium (DMEM)"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a double-blind , randomized, controlled, two-arm study aiming to evaluate the safety\n      and efficacy of Polyheal-2 vs PolyHeal, in once daily application as compared to historical\n      control. The study will enroll adult subjects with post traumatic/post surgical hard to heal\n      wounds who meet the entrance criteria which will be followed for 12 weeks."
        }, 
        "brief_title": "A Study, Performed in Subjects With Post Traumatic-post Surgical Hard to Heal/Chronic Wounds, to Evaluate the Safety and Efficacy of PolyHeal-2 Versus PolyHeal in Once Daily Regimen", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Surgical Wound Dehiscence", 
        "condition_browse": {
            "mesh_term": "Surgical Wound Dehiscence"
        }, 
        "detailed_description": {
            "textblock": "Subjects will undergo screenibg period of up to two weeks. Following to eligibilidy\n      confirmation subjects will be randomized into one of the two treatment groups and treated\n      with study device once daily for 4 weeks.\n\n      Continuation of study device for additional period is based on wound healing progression and\n      under investigator's discretion.\n\n      Subjects will be followed up weekly following to 4 weeks of active treatment for additional\n      8 weeks untol week 12."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Hard to heal/chronic post traumatic post surgical wound refractory to healing at\n             least 4 weeks prior to study treatment (one or more target wound/s will be eligible\n             per each subject to be treated by the same agent)\n\n          -  Subjects who are able to read, understand, and sign the informed consent form. In\n             case of compromised mental capacity, approval and signature of a legal guardian is\n             required.\n\n        Exclusion Criteria:\n\n          -  Presence of a systemic infection or significant local infection with copious purulent\n             drainage, fluids drainage, gangrene, or cellulites,  or necrosis at the target wound\n             site, as well as nonviable tissue, sinus tracts or tunnels that cannot be removed by\n             debridement.\n\n          -  Wounds with exposed bones, tendons or ligaments\n\n          -  Wounds with exposed orthopedic implants\n\n          -  Wounds with exposed breast prostheses\n\n          -  Uncontrolled diabetes with HbA1c >11%\n\n          -  Subjects with BMI greater than 35kg/m2\n\n          -  Woman who are pregnant or nursing, or of childbearing potential and are not using\n             adequate contraception\n\n          -  Participation in another clinical drug/device trial within 30 days prior to the\n             Screening visit or during this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01679678", 
            "org_study_id": "MWPH-2012-08-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "PolyHeal 2", 
                "description": "PolyHeal is a sterile medical device", 
                "intervention_name": "PolyHeal 2", 
                "intervention_type": "Device", 
                "other_name": [
                    "PolyHeal", 
                    "PolyHeal is a sterile medical device"
                ]
            }, 
            {
                "arm_group_label": "PolyHeal", 
                "description": "PolyHeal is a sterile medical device that is comprised of negatively charged 5-micron polystyrene microspheres suspended in", 
                "intervention_name": "Polyheal", 
                "intervention_type": "Device", 
                "other_name": "PolyHeal is a sterile medical device that is comprised of negatively charged 5-micron polystyrene microspheres suspended in DMEM"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 1, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beer Sheva", 
                        "country": "Israel"
                    }, 
                    "name": "Soroka Medical Center"
                }, 
                "investigator": {
                    "last_name": "Alex Berezovsky, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Naharia", 
                        "country": "Israel"
                    }, 
                    "name": "Western Galilee Hospital"
                }, 
                "investigator": {
                    "last_name": "Eyal Gur, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eyal Gur, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Tel Aviv", 
                        "country": "Israel"
                    }, 
                    "name": "Souraski Medical Center"
                }, 
                "investigator": {
                    "last_name": "Eyal Gur, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double Blind, Randomized, Controlled Study, Performed in Subjects With Post Traumatic-post Surgical Hard to Heal/Chronic Wounds, to Evaluate the Safety and Efficacy of Polyheal-2 vs PolyHeal in Once Daily Regimen", 
        "overall_contact": {
            "email": "dinak@mediwound.co.il", 
            "last_name": "Dina Kofler"
        }, 
        "overall_contact_backup": {
            "last_name": "Alla Latovsky allal@mediwound.co,il, RN study coordinator"
        }, 
        "overall_official": [
            {
                "affiliation": "Head of Department of Plastic and reconstructive surgery", 
                "last_name": "Alex Berezovsky, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Head of Plastic and Reconstructive Surgery Department, Souraski Medical Center", 
                "last_name": "Eyal Gur, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Head of Plastic Surgery Department Western Galilee Hospital", 
                "last_name": "Leonid Kogan, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Achievement of at least (\u2265)75% viable granulation tissue (grade 7 or 8 on the granulometer scale) after 4 weeks of study treatment (active phase)", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01679678"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "MediWound Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MediWound Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}